Use of menopausal hormone therapy beyond age 65 years and its effects on women's health outcomes by types, routes, and doses

Abstract

Among senior Medicare women, the implications of menopausal hormone therapy use beyond age 65 years vary by types, routes, and strengths. In general, risk reductions appear to be greater with low rather than medium or high doses, vaginal or transdermal rather than oral preparations, and with E2 rather than conjugated estrogen.